See more : Visco Vision Inc. (6782.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Grifols, S.A. (GIFOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Grifols, S.A., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Investeringsforeningen Wealth Invest – Timeinvest Sustainable Opportunities AKL (WEITISOP.CO) Income Statement Analysis – Financial Results
- Ivanhoe Electric Inc. (IE.TO) Income Statement Analysis – Financial Results
- Punjab National Bank (PNB.NS) Income Statement Analysis – Financial Results
- ktcs corporation (058850.KS) Income Statement Analysis – Financial Results
- AXIOS Sustainable Growth Acquis (AXAC-RI) Income Statement Analysis – Financial Results
Grifols, S.A. (GIFOF)
About Grifols, S.A.
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.59B | 6.06B | 4.93B | 5.34B | 5.10B | 4.49B | 4.32B | 4.05B | 3.93B | 3.36B | 2.74B | 2.62B | 1.80B | 990.73M | 913.19M | 814.31M | 703.29M | 648.80M | 524.28M |
| Cost of Revenue | 4.10B | 3.83B | 2.97B | 3.08B | 2.76B | 2.44B | 2.17B | 2.14B | 2.00B | 1.66B | 1.32B | 1.29B | 466.70M | 227.60M | 172.04M | 175.68M | 179.43M | 203.17M | 153.90M |
| Gross Profit | 2.49B | 2.23B | 1.96B | 2.26B | 2.34B | 2.05B | 2.15B | 1.91B | 1.93B | 1.70B | 1.42B | 1.33B | 1.33B | 763.13M | 741.15M | 638.63M | 523.87M | 445.63M | 370.38M |
| Gross Profit Ratio | 37.84% | 36.80% | 39.78% | 42.23% | 45.92% | 45.68% | 49.84% | 47.22% | 49.08% | 50.64% | 51.71% | 50.73% | 74.01% | 77.03% | 81.16% | 78.43% | 74.49% | 68.68% | 70.65% |
| Research & Development | 395.28M | 361.14M | 354.88M | 294.22M | 276.02M | 240.66M | 288.32M | 197.62M | 224.19M | 180.75M | 123.27M | 124.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.26B | 523.30M | 436.67M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 877.67M | 436.43M | 405.08M | 350.20M | 300.04M | 313.16M | 265.04M |
| Selling & Marketing | 0.00 | 667.12M | 624.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40.24M | 35.66M | 36.10M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.26B | 1.19B | 1.06B | 985.62M | 942.82M | 814.78M | 860.35M | 775.27M | 736.44M | 660.77M | 558.46M | 545.07M | 917.91M | 472.09M | 441.18M | 350.20M | 300.04M | 313.16M | 265.04M |
| Other Expenses | 40.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.70B | 1.53B | 1.40B | 1.28B | 1.22B | 1.06B | 1.15B | 972.88M | 960.63M | 841.53M | 681.73M | 669.52M | 1.05B | 555.00M | 516.10M | 410.19M | 351.43M | 359.45M | 306.65M |
| Cost & Expenses | 5.79B | 5.36B | 4.37B | 4.36B | 3.98B | 3.49B | 3.31B | 3.11B | 2.96B | 2.50B | 2.01B | 1.96B | 1.52B | 782.60M | 688.14M | 585.87M | 530.86M | 562.62M | 460.55M |
| Interest Income | 135.86M | 33.86M | 11.55M | 8.02M | 114.20M | 14.00M | 9.68M | 9.93M | 5.84M | 3.07M | 4.87M | 1.68M | 5.76M | 2.88M | 6.51M | 2.21M | 2.85M | 4.67M | 3.43M |
| Interest Expense | 516.06M | 362.63M | 233.81M | 222.92M | 324.38M | 274.16M | 249.53M | 228.80M | 224.61M | 209.49M | 215.35M | 284.12M | 200.56M | 33.39M | 12.39M | 12.67M | 9.52M | 8.08M | 8.28M |
| Depreciation & Amortization | 441.92M | 407.86M | 359.77M | 321.53M | 302.46M | 228.61M | 215.49M | 201.87M | 189.76M | 189.47M | 128.47M | 129.13M | 90.64M | 45.78M | 39.55M | 33.26M | 31.53M | 29.36M | 26.90M |
| EBITDA | 1.18B | 1.21B | 922.28M | 1.30B | 1.42B | 1.22B | 1.28B | 1.14B | 1.16B | 1.05B | 864.59M | 776.27M | 341.43M | 233.65M | 255.94M | 243.67M | 190.71M | 100.94M | 76.00M |
| EBITDA Ratio | 17.93% | 18.34% | 19.37% | 25.45% | 29.22% | 26.89% | 27.67% | 28.20% | 29.02% | 30.64% | 30.77% | 30.12% | 20.78% | 24.35% | 28.15% | 29.92% | 27.12% | 13.52% | 12.32% |
| Operating Income | 799.40M | 805.68M | 595.06M | 996.13M | 1.13B | 994.12M | 1.00B | 939.41M | 970.37M | 857.69M | 736.12M | 660.08M | 278.86M | 209.68M | 226.53M | 202.96M | 146.35M | 100.49M | 73.59M |
| Operating Income Ratio | 12.13% | 13.29% | 12.06% | 18.65% | 22.19% | 22.16% | 23.24% | 23.20% | 24.66% | 25.56% | 26.85% | 25.18% | 15.53% | 21.16% | 24.81% | 24.92% | 20.81% | 15.49% | 14.04% |
| Total Other Income/Expenses | -575.38M | -444.42M | -244.61M | -117.50M | -314.26M | -268.28M | -307.62M | -226.66M | -280.12M | -268.01M | -238.58M | -272.14M | -198.84M | -51.90M | -22.53M | -30.69M | -22.77M | -36.98M | -32.77M |
| Income Before Tax | 224.02M | 361.26M | 350.45M | 878.63M | 817.10M | 725.84M | 695.72M | 712.75M | 690.25M | 589.68M | 497.54M | 387.95M | 80.02M | 157.78M | 203.99M | 172.27M | 123.59M | 63.51M | 40.82M |
| Income Before Tax Ratio | 3.40% | 5.96% | 7.10% | 16.45% | 16.03% | 16.18% | 16.11% | 17.60% | 17.54% | 17.57% | 18.15% | 14.80% | 4.46% | 15.93% | 22.34% | 21.16% | 17.57% | 9.79% | 7.79% |
| Income Tax Expense | 43.35M | 90.11M | 85.13M | 169.64M | 168.46M | 131.44M | 34.41M | 168.21M | 158.81M | 122.60M | 155.48M | 132.57M | 29.80M | 42.52M | 56.42M | 50.15M | 35.24M | 17.82M | 15.32M |
| Net Income | 59.32M | 208.28M | 188.73M | 618.55M | 625.15M | 596.64M | 662.70M | 545.46M | 532.15M | 470.25M | 345.55M | 256.69M | 50.31M | 115.51M | 147.97M | 121.73M | 87.77M | 45.39M | 25.56M |
| Net Income Ratio | 0.90% | 3.43% | 3.83% | 11.58% | 12.26% | 13.30% | 15.35% | 13.47% | 13.52% | 14.01% | 12.60% | 9.79% | 2.80% | 11.66% | 16.20% | 14.95% | 12.48% | 7.00% | 4.87% |
| EPS | 0.09 | 0.31 | 0.28 | 0.90 | 0.91 | 0.87 | 0.97 | 0.80 | 0.78 | 0.69 | 0.51 | 0.38 | 0.16 | 0.45 | 0.31 | 0.25 | 0.18 | 0.11 | 0.06 |
| EPS Diluted | 0.09 | 0.31 | 0.28 | 0.90 | 0.91 | 0.87 | 0.97 | 0.80 | 0.78 | 0.69 | 0.51 | 0.38 | 0.16 | 0.45 | 0.31 | 0.25 | 0.18 | 0.11 | 0.06 |
| Weighted Avg Shares Out | 679.09M | 678.41M | 678.54M | 684.54M | 685.12M | 684.71M | 684.20M | 683.23M | 683.55M | 685.34M | 681.01M | 685.40M | 308.04M | 258.90M | 483.83M | 486.73M | 489.97M | 429.58M | 421.25M |
| Weighted Avg Shares Out (Dil) | 679.09M | 678.41M | 678.54M | 684.54M | 685.12M | 684.71M | 684.24M | 683.23M | 683.92M | 685.34M | 681.01M | 685.40M | 308.04M | 258.90M | 483.83M | 486.73M | 489.97M | 429.58M | 421.25M |
Source: https://incomestatements.info
Category: Stock Reports